Denali (DNLI) Director Peter S. Klein Receives RSU and Derivative Award

What Happened
Peter S. Klein, a director of Denali Therapeutics (DNLI), was awarded equity on 2026-06-03: 6,408 restricted stock units (RSUs) and a separate 19,226-share derivative award. Both awards were recorded with an acquisition price of $0.00, consistent with executive/director compensation grants (no cash paid).

Key Details

• Transaction date: 2026-06-03; Form 4 filed 2026-06-05 (appears timely).
• Awards: 6,408 RSUs (unvested) and 19,226 shares reported as a derivative acquisition; both listed at $0.00.
• Vesting: 100% of these awards vest upon the earlier of (i) one year after the grant date or (ii) the day before the issuer’s next annual meeting of stockholders. (See filing footnotes.)
• Ownership after transaction: total shares owned after transaction not specified in the Form 4.
• Footnote highlights: each share is represented by an RSU and a contingent right to receive one share; the 6,408 RSUs are unvested; the derivative award follows the same one-year/annual-meeting vesting schedule.

Context
These entries are grants (awards), not open-market purchases or sales. Grants issued at $0.00 are typical for compensation and do not reflect an immediate cash outlay or sale — the holdings remain unvested until the stated vesting condition is met. Grants are informative about company compensation practices but do not by themselves indicate near-term buying or selling behavior.